Risedronate reduces the risk of first vertebral fracture in osteoporotic women

R. P. Heaney, T. M. Zizic, I. Fogelman, W. P. Olszynski, P. Geusens, C. Kasibhatla, N. Alsayed, G. Isaia, M. W. Davie, C. H. Chesnut

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score = -3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n = 328) or placebo (n = 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P = 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P = 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P = 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.

Original languageEnglish
Pages (from-to)501-505
Number of pages5
JournalOsteoporosis International
Volume13
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Osteoporotic Fractures
Risk Reduction Behavior
Placebos
Osteoporosis
Controlled Clinical Trials
Menopause
Vitamin D
Bone Density
Spine
Risedronate Sodium
Confidence Intervals
Calcium
Incidence
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Heaney, R. P., Zizic, T. M., Fogelman, I., Olszynski, W. P., Geusens, P., Kasibhatla, C., ... Chesnut, C. H. (2002). Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporosis International, 13(6), 501-505. https://doi.org/10.1007/s001980200061

Risedronate reduces the risk of first vertebral fracture in osteoporotic women. / Heaney, R. P.; Zizic, T. M.; Fogelman, I.; Olszynski, W. P.; Geusens, P.; Kasibhatla, C.; Alsayed, N.; Isaia, G.; Davie, M. W.; Chesnut, C. H.

In: Osteoporosis International, Vol. 13, No. 6, 2002, p. 501-505.

Research output: Contribution to journalArticle

Heaney, RP, Zizic, TM, Fogelman, I, Olszynski, WP, Geusens, P, Kasibhatla, C, Alsayed, N, Isaia, G, Davie, MW & Chesnut, CH 2002, 'Risedronate reduces the risk of first vertebral fracture in osteoporotic women', Osteoporosis International, vol. 13, no. 6, pp. 501-505. https://doi.org/10.1007/s001980200061
Heaney RP, Zizic TM, Fogelman I, Olszynski WP, Geusens P, Kasibhatla C et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporosis International. 2002;13(6):501-505. https://doi.org/10.1007/s001980200061
Heaney, R. P. ; Zizic, T. M. ; Fogelman, I. ; Olszynski, W. P. ; Geusens, P. ; Kasibhatla, C. ; Alsayed, N. ; Isaia, G. ; Davie, M. W. ; Chesnut, C. H. / Risedronate reduces the risk of first vertebral fracture in osteoporotic women. In: Osteoporosis International. 2002 ; Vol. 13, No. 6. pp. 501-505.
@article{0b695bc8d17c42cea499f9cb6e750b00,
title = "Risedronate reduces the risk of first vertebral fracture in osteoporotic women",
abstract = "Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score = -3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n = 328) or placebo (n = 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4{\%} in the women treated with placebo and 2.6{\%} in those treated with risedronate 5 mg (risk reduction of 75{\%}, 95{\%} confidence interval 37{\%} to 90{\%}; P = 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70{\%}, 95{\%} CI 8{\%} to 90{\%}; P = 0.030) and in those with a mean age of 76 years (risk reduction of 80{\%}, 95{\%} CI 7{\%} to 96{\%}; P = 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.",
author = "Heaney, {R. P.} and Zizic, {T. M.} and I. Fogelman and Olszynski, {W. P.} and P. Geusens and C. Kasibhatla and N. Alsayed and G. Isaia and Davie, {M. W.} and Chesnut, {C. H.}",
year = "2002",
doi = "10.1007/s001980200061",
language = "English",
volume = "13",
pages = "501--505",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "6",

}

TY - JOUR

T1 - Risedronate reduces the risk of first vertebral fracture in osteoporotic women

AU - Heaney, R. P.

AU - Zizic, T. M.

AU - Fogelman, I.

AU - Olszynski, W. P.

AU - Geusens, P.

AU - Kasibhatla, C.

AU - Alsayed, N.

AU - Isaia, G.

AU - Davie, M. W.

AU - Chesnut, C. H.

PY - 2002

Y1 - 2002

N2 - Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score = -3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n = 328) or placebo (n = 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P = 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P = 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P = 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.

AB - Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score = -3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n = 328) or placebo (n = 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P = 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P = 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P = 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.

UR - http://www.scopus.com/inward/record.url?scp=0036303635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036303635&partnerID=8YFLogxK

U2 - 10.1007/s001980200061

DO - 10.1007/s001980200061

M3 - Article

VL - 13

SP - 501

EP - 505

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 6

ER -